Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune response, reducing natural killer (NK) cells without affecting efficacy or...

詳細記述

保存先:
書誌詳細
出版年:Leukemia
主要な著者: Casneuf, Tineke, Adams, Homer C., van de Donk, Niels W.C.J., Abraham, Yann, Bald, Jaime, Vanhoof, Greet, Van der Borght, Koen, Smets, Tina, Foulk, Brad, Nielsen, Karl C., Rusbuldt, Joshua, Axel, Amy, Lysaght, Andrew, Ceulemans, Hugo, Stevenaert, Frederik, Usmani, Saad Z., Plesner, Torben, Avet-Loiseau, Herve, Nijhof, Inger, Mutis, Tuna, Schecter, Jordan M., Chiu, Christopher, Bahlis, Nizar J.
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group UK 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7862054/
https://ncbi.nlm.nih.gov/pubmed/32457357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0855-4
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料